Toral Parikh, MD
Geriatric Medicine · Austin, TXNPI 1477817930
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 27.8% of the total. 2025 is the largest year on record at $826, 8.1 times the $102 reported in 2023.
Across 56 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$333
- Novo Nordisk$258
- AstraZeneca$95
- Corium, LLC$60
- AbbVie$50
- Dexcom, Inc.$42
- plus $357 from 14 others
What the payments were for
- Food & beverage$1,195100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 10 | $333 |
| Novo Nordisk | 15 | $258 |
| AstraZeneca | 5 | $95 |
| Corium, LLC | 3 | $60 |
| AbbVie | 2 | $50 |
| Dexcom, Inc. | 2 | $42 |
| Exact Sciences | 2 | $38 |
| Bayer | 2 | $37 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Lilly USA, LLC | 2 | $36 |
| Amneal Pharmaceuticals LLC | 2 | $34 |
| Boehringer Ingelheim | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| GSK | 1 | $20 |
| Pfizer | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Amgen | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
How this compares
$1,195 in reported general payments places this provider in the 80th percentile of 275 geriatric medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 23 | $27,923 |
| JardianceEmpagliflozin | 13 | $23,129 |
| MyrbetriqMirabegron | 24 | $17,243 |
| MounjaroTirzepatide | 15 | $15,846 |
| EliquisApixaban | 15 | $14,869 |
| Spiriva RespimatTiotropium Bromide | 17 | $10,088 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,782 |
| Estradiol | 19 | $2,364 |
| Levothyroxine Sodium | 144 | $1,406 |
| Gabapentin | 82 | $1,387 |
| Mirtazapine | 58 | $1,209 |
| Atorvastatin Calcium | 123 | $794 |
| Duloxetine Hcl | 40 | $763 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $740 |
| Escitalopram Oxalate | 70 | $600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $30 | $33,21730 claims |
| Novo NordiskOzempic | $258 | $27,92323 claims |
| Lilly USA, LLCMounjaro | $36 | $15,84615 claims |
| PfizerEliquis | $17 | $14,86915 claims |
| GSKTrelegy Ellipta | $20 | $8,78211 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $34 | $1,406144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 275 geriatric medicine providers in Texas.
Other geriatric medicine in Austin
- Mauricio Gonzalez-AriasAustin$825K
- Kimberly ChouAustin$1K
- Eberenne IgbokwePearland$124K
- Diana KerwinDallas$81K
- David SmithBrownwood$19K
- Alejandro ArizmendiHelotes$15K
- Rosa VizcarraSan Antonio$9K
- George TaffetHouston$9K
- John CarrollCorpus Christi$8K
- Santos SoberonBeaumont$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.